Skip to main content

Advertisement

SpringerLink
Log in

Limited efficacy of intratumoral IL-2 applied to large melanoma metastases

  • Letter to the Editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

The Original Article was published on 24 July 2014

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Weide B, Eigentler TK, Pflugfelder A, Leiter U, Meier F, Bauer J, Schmidt D, Radny P, Pfohler C, Garbe C (2011) Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother 60(4):487–493. doi:10.1007/s00262-010-0957-3

    Article  PubMed  CAS  Google Scholar 

  2. Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C (2014) Intralesional treatment of Stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunological responses. Cancer Immunol Res. doi:10.1158/2326-6066.cir-13-0206

  3. Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pfohler C, Pawelec G, Garbe C (2010) High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer 116(17):4139–4146. doi:10.1002/cncr.25156

    Article  PubMed  CAS  Google Scholar 

  4. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89(9):1620–1626. doi:10.1038/sj.bjc.6601320

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Antony PA, Restifo NP (2005) CD4+ CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 28(2):120–128

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105–2116

    PubMed  CAS  Google Scholar 

  7. Schwager K, Hemmerle T, Aebischer D, Neri D (2013) The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol 133(3):751–758. doi:10.1038/jid.2012.376

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

G. Elia is employed by the Philogen group. D. Neri is a co-founder and shareholder of Philogen, the biotech company that has licensed the L19–IL2 antibody from the ETH Zurich. B. Weide and T. Eigentler received compensation from the Philogen group for advisory services. C. Garbe received compensation from the Philogen group for advisory services, for patient treatment and in his role as coordinating investigator of clinical trials.

Author information

Authors and Affiliations

  1. Department of Dermatology, University Medical Center, Liebermeisterstrasse 25, 72076, Tübingen, Germany

    Benjamin Weide, Thomas Kurt Eigentler & Claus Garbe

  2. Philochem AG, Otelfingen, Switzerland

    Giuliano Elia

  3. ETH Zurich, Zurich, Switzerland

    Dario Neri

Authors
  1. Benjamin Weide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Kurt Eigentler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giuliano Elia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dario Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin Weide.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weide, B., Eigentler, T.K., Elia, G. et al. Limited efficacy of intratumoral IL-2 applied to large melanoma metastases. Cancer Immunol Immunother 63, 1231–1232 (2014). https://doi.org/10.1007/s00262-014-1584-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-014-1584-1

Keywords

Search

Navigation